Next Article in Journal
CD81-Receptor Associations — Impact for Hepatitis C Virus Entry and Antiviral Therapies
Next Article in Special Issue
Matrix and Backstage: Cellular Substrates for Viral Vaccines
Previous Article in Journal
The Evolution of Adenoviral Vectors through Genetic and Chemical Surface Modifications
Previous Article in Special Issue
HSV-2 Vaccine: Current Status and Insight into Factors for Developing an Efficient Vaccine
Article Menu

Export Article

Open AccessArticle
Viruses 2014, 6(2), 856-874;

Anti-Tumor Effects of an Oncolytic Adenovirus Expressing Hemagglutinin-Neuraminidase of Newcastle Disease Virus in Vitro and in Vivo

2,5,* , 1,†,* and 2,5,†,*
Department of Gastroenterology, The First Hospital of Jilin University, Changchun 130021, China
Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122, China
Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, Changchun 130031, China
Head and Neck Surgery, The Tumor hospital of Jilin province, Changchun 130001, China
The Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun 130021, China
Senior authorship.
Authors to whom correspondence should be addressed.
Received: 20 January 2014 / Revised: 7 February 2014 / Accepted: 8 February 2014 / Published: 18 February 2014
(This article belongs to the Special Issue Virus-based Vaccines)
Full-Text   |   PDF [1352 KB, uploaded 12 May 2015]   |  


Oncolytic virotherapy has been an attractive drug platform for targeted therapy of cancer over the past few years. Viral vectors can be used to target and lyse cancer cells, but achieving good efficacy and specificity with this treatment approach is a major challenge. Here, we assessed the ability of a novel dual-specific anti-tumor oncolytic adenovirus, expressing the hemagglutinin-neuraminidase (HN) gene from the Newcastle disease virus under the human telomerase reverse transcriptase (hTERT) promoter (Ad-hTERTp-E1a-HN), to inhibit esophageal cancer EC-109 cells in culture and to reduce tumor burden in xenografted BALB/c nude mice. In vitro, infection with Ad-hTERT-E1a-HN could inhibit the growth of EC-109 cells significantly and also protect normal human liver cell line L02 from growth suppression in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Ad-hTERT-E1a-HN also effectively and selectively decreased the sialic acid level on EC-109 cells, but not on L02 cells. Furthermore, Ad-hTERT-E1a-HN was shown to induce the apoptosis pathway via acridine orange and ethidium bromide staining (AO/EB staining), increase reactive oxygen species (ROS), reduce mitochondrial membrane potential and release cytochrome c. In vivo, xenografted BALB/c nude mice were treated via intratumoral or intravenous injections of Ad-hTERT-E1a-HN. Although both treatments showed an obvious suppression in tumor volume, only Ad-hTERT-E1a-HN delivered via intratumoral injection elicited a complete response to treatment. These results reinforced previous findings and highlighted the potential therapeutic application of Ad-hTERT-E1a-HN for treatment of esophageal cancer in clinical trials. View Full-Text
Keywords: anti-tumor; hemagglutinin-neuraminidase gene; apoptosis; oncolytic adenoviruses; esophageal cancer anti-tumor; hemagglutinin-neuraminidase gene; apoptosis; oncolytic adenoviruses; esophageal cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

He, D.; Sun, L.; Li, C.; Hu, N.; Sheng, Y.; Chen, Z.; Li, X.; Chi, B.; Jin, N. Anti-Tumor Effects of an Oncolytic Adenovirus Expressing Hemagglutinin-Neuraminidase of Newcastle Disease Virus in Vitro and in Vivo. Viruses 2014, 6, 856-874.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top